help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mccauley, L. K.
Right arrow Articles by McCabe, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mccauley, L. K.
Right arrow Articles by McCabe, L. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOHEXIMIDE
*PARATHYROID HORMONE
Endocrinology Vol. 142, No. 5 1975-1981
Copyright © 2001 by The Endocrine Society

ARTICLES

Parathyroid Hormone Stimulates fra-2 Expression in Osteoblastic Cells in Vitro and in Vivo1

L. K. Mccauley, A. J. Koh-Paige, H. Chen, C. Chen, C. Ontiveros, R. Irwin and L. R. McCabe

Department of Periodontics/Prevention/Geriatrics (L.K.M., A.J.K., H.C., C.C.), University of Michigan, Ann Arbor, Michigan 48109-1078; and Department of Physiology (C.O., R.I., L.R.M.), Michigan State University, East Lansing, Michigan 48824-1101

Address all correspondence and requests for reprints to: Laurie K. McCauley, Department of Periodontics/Prevention/Geriatrics, University of Michigan, 1011 North University Avenue, Ann Arbor, Michigan 48109-1078. E-mail: mccauley{at}umich.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PTH and PTH-related protein (PTHrP) are key mediators of skeletal development and homeostasis through their activation of the PTH-1 receptor. Previous studies have found that several AP-1 family members are regulated by PTH, such as c-fos, fra-1, and c-jun. There are numerous genes in the bone microenvironment that contain AP-1 sites, and different Fos family members are reported to have opposing transcriptional activities at AP-1 sites. The purpose of this study was to identify the effects of PTH on expression of the AP-1 protein complex member, fra-2, to extend our understanding of transcriptional regulators of PTH action. PTH induction of fra-2 messenger RNA (mRNA) levels in MC3T3-E1 preosteoblastic cells was maximal with 0.1 µM PTH (1–34). The expression in vitro was greatest 1 h after treatment and was present with N-terminal PTH but not PTH (7–34) or (53–84). Cycloheximide treatment induced fra-2 expression, and actinomycin D inhibited basal and PTHrP-induced expression. AP-1 protein in nuclear extracts of MC3T3-E1 cells was increased with PTH treatment at 3 h and consisted of high levels of Fra-2 protein, as evidenced by a supershift in an electrophoretic mobility shift assay and Western blot analysis. Up-regulation of steady-state fra-2 mRNA was also noted in vivo, where injection of PTH (1–34) (20 µg) resulted in a more-than-7-fold maximal increase in fra-2 mRNA expression in the calvaria of mice, after 1 h of treatment. These data add to the transcriptional mediators induced by PTH and suggest that the interplay of AP-1 family members will provide insight into regulatory pathways of PTH and PTHrP for their anabolic and catabolic actions in bone.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
PTH IS THE major systemic calcium-regulating hormone with well-documented anabolic and catabolic effects in bone. PTH-related protein (PTHrP) is a regulator of cartilage development, where it is thought to promote proliferation of growth plate chondrocytes (1, 2). Although animal studies of PTH and PTHrP action have provided insight into their actions in skeletal tissues, the mechanisms of their effects are still unclear. A better understanding of the downstream events in signaling of the PTH-1 receptor is necessary to clarify anabolic and catabolic actions in bone.

The c-fos protooncogene is an immediate-early response gene that undergoes rapid transcriptional activation by PTH (3, 4, 5). When PTH is administered to rats in vivo, messenger RNA (mRNA) for c-fos is detected in PTH-1 receptor bearing cells within 1 h of administration (6, 7). It is clear that c-fos plays a major role in bone. Early in development, c-fos is expressed primarily in the growth regions of developing cartilage and bone. Mice with ablation of the c-fos gene develop osteopetrosis and lack osteoclasts; and mice that overexpress c-fos develop chondroblastic osteosarcomas (8, 9).

To date, seven proteins are included in the AP-1 family of transcription factors (10). Before binding DNA, Fos proteins (c-Fos, FosB, Fra-1, and Fra-2) form heterodimers with Jun proteins (c-Jun, Jun B, and Jun D) through a leucine zipper motif (11). AP-1 sites are located in the promoters of several genes expressed by osteoblasts, including osteocalcin, interleukin-6, and macrophage colony-stimulating factor (12, 13, 14). Expression of Jun and Fos family members is modulated during osteoblast proliferation and differentiation; and recently, these proteins have been shown to be key mediators in the positive regulation of bone formation (15, 16, 17). Nuclear proteins for all of the AP-1 family members are high during osteoblast proliferation. During differentiation, levels decline, and Fra-2 and Jun D are the principal proteins present (18). Modulation of Fra-2 expression by overexpression or antisense oligonucleotide treatment suggests that Fra-2 is an important factor involved in the development of the mature osteoblast phenotype. Most studies have focused on the ability of PTH to stimulate c-fos or c-jun gene expression, but other AP-1 family members may also be regulated by PTH. PTH has also been found to increase fra-1, fos B, and jun-B (19), but there are no reports regarding the effects of PTH on fra-2. The purpose of this study was to evaluate the effects of PTH on fra-2 expression in bone in vitro and in vivo.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture
MC3T3-E1 cells were obtained from Dr. M. Kumegawa via Dr. Renny Franceschi (University of Michigan, Ann Arbor, MI) and maintained as described (20). Primary murine calvarial cells were isolated via collagenase digestion as described, and the third digest was used without passage (21). Cells were plated at 50,000/cm2 in {alpha}-modified Eagle’s medium with 10% FBS, 100 U/ml penicillin, and streptomycin and were induced to differentiate (4–7 days) for maximal PTH-1 receptor expression (21) with the addition of 50 µg/ml L-ascorbic acid (Fisher Scientific, Itasca, IL) and 10 mM ß-glycerophosphate (Sigma, St. Louis, MO).

Gene expression studies in vitro
Total RNA was isolated from MC3T3-E1 or primary murine calvarial cells treated with various doses of PTH (1–34) for 0–24 h. Northern blot analyses were performed as described (4). Briefly, total RNA was isolated by the guanidinium isothiocyanate method and quantified by spectrophotometry. Total RNA (10 µg) was electrophoresed on 1.2% agarose-formaldehyde gels, transferred to nylon membranes (Duralon U.V.; Stratagene, La Jolla, CA), and cross-linked with UV light. Nylon membranes were hybridized with a complementary DNA probe for fra-2 (18) or c-fos (4) labeled with [{alpha}-32P] deoxycytidine triphosphate, using random primer labeling (Amersham Pharmacia Biotech, Piscataway, NJ). Blots were stripped and reprobed with a complementary DNA for 18S ribosomal RNA (22) to control for RNA loading. After hybridization and washing, radioactive cpm were quantified using an Instant Imager (Packard Instrument Co., San Diego, CA). Blots were also exposed to Biomax or X-OMAT film (Eastman Kodak Co., Rochester, NY) at -80 C for 24–72 h, and band intensity was determined by image analysis.

Gene expression studies in vivo
Mice were injected with 50 µl of 0.9% saline solution alone (vehicle) or vehicle containing 20 µg PTH (1–34) sc over the calvaria. Noninjected controls were also evaluated. Mice were killed at the indicated time periods and calvaria were dissected, flash-frozen in liquid N2, and processed using a mortar and pestle for RNA isolation, as described (23). Northern blot analysis was performed as above.

Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated from MC3T3-E1 cells stimulated with PTH (1–34) (0.1 µM) or PTHrP (1–34) (0.1 µM) for 3 h, via hypotonic lysis, as described (24). Protein concentrations were determined by the Bradford assay (Pierce Chemical Co., Rockford, IL). Nuclear extracts (2.5 µg) were incubated, for 20 min at 24 C, with 50,000 cpm 32P-end labeled (T4-polynucleotide kinase; Amersham Pharmacia Biotech) AP-1 oligonucleotide (CGCTTGATGAGTCAGCCGGAA) with or without an excess of unlabeled competitor oligonucleotide. For supershift experiments, antibodies (4 µg) for Fra-2, Fra-1, Fos, FosB (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and cAMP response element binding protein (CREB) (Rockland Immunochemicals, Gilbertsville, PA) were added to binding reactions and incubated overnight on ice. The samples were loaded on prerun (30 min; 150 V) 5% polyacrylamide gels and run for 3 h at 150V at 4 C. Gels were dried and exposed to films (4–10 h) at -80 C.

Western blot analysis
Nuclear extracts (30 µg/lane) were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membrane (Trans-blot transfer medium, Bio-Rad Laboratories, Inc., Hercules, CA). Membranes were blocked in 7% nonfat dried milk in Tris-buffered saline (TBS) overnight at 4 C. After two washes in TBS plus 0.05% Tween-20, membranes were incubated overnight at 4 C in a 1:100 dilution of Fra-2 antibody (Santa Cruz Biotechnology, Inc.) in TBS plus 1% BSA. Membranes were washed four times in TBS and incubated for 45 min with secondary antibody. After three washes in TBS, blots were developed by chemiluminescent detection according to protocols supplied by the manufacturer (ECL, Amersham International, Aylesbury, UK).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
PTH-induced fra-2 expression in vitro
PTH treatment (1–2 h) stimulated an increase in steady-state mRNA for fra-2 in MC3T3-E1 osteoblastic cells and primary murine calvarial cell cultures (Fig. 1Go). Detectable increases were noted at a dose of 10 pM and were greater than 4-fold at 1 µM. The level of c-fos mRNA, a known PTH-regulated transcription factor (4), in the same cell cultures was also dose dependently increased. Relative to fra-2 expression, PTH-induced c-fos expression was an average of 2-fold higher at concentrations greater than 100 pM. An investigation of the time response of fra-2 mRNA expression to PTH (1–34)-treatment indicated that gene expression was rapid, with maximal increase at 1 h. (Fig. 2Go). The PTH-stimulated up-regulation in fra-2 mRNA gene expression was found with PTH (1–34) but not with PTH (7–34) or PTH (53–84) (Fig. 3Go). PTHrP (1–34) stimulated fra-2 at equivalent doses as PTH and forskolin-treatment also stimulated fra-2 expression (data not shown).



View larger version (15K):
[in this window]
[in a new window]
  		Figure 1. Northern blot analysis of dose effect of PTH (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) on steady-state fra-2 mRNA levels. Cells were treated with 1.0 pM–1.0 µM PTH or vehicle control. Total RNA was isolated, and Northern blot analysis was performed to detect fra-2 gene expression. A, Representative fra-2 blot from MC3T3-E1 cells treated for 1 h; B, plot of mean ± SEM of cpm [fra-2, c-fos relative to 18S, then expressed as treatment/control (T/C)] from three experiments; C, representative blot from primary calvarial cells treated with PTH (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) (0.1 µM) for 2 h; D, plot of mean ± SEM of cpm (fra-2, relative to 18S, then expressed as T/C) from primary calvarial cells isolated and treated separately.

 


View larger version (45K):
[in this window]
[in a new window]
  		Figure 2. Northern blot analysis of temporal regulation (0–24 h) for steady-state fra-2 mRNA levels induced by PTH (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 )(0.1 µM). MC3T3-E1 cells were treated for the indicated time points, total RNA was isolated, and Northern blot analysis was performed to detect fra-2 gene expression. A, Representative fra-2 blot; B, plot of mean ± SEM of cpm (fra-2, relative to 18S, then expressed as T/C) from two experiments.

 


View larger version (25K):
[in this window]
[in a new window]
  		Figure 3. Northern blot analysis of steady-state fra-2 mRNA levels induced by PTH analogs (0.1 µM). MC3T3-E1 cells were treated with PTH analogs for 1 h, followed by total RNA isolation and Northern blot analysis for fra-2 gene expression. A, Representative blot; B, plot of mean ± SEM of cpm (fra-2, relative to 18S, then expressed as T/C) from three experiments.

 
To evaluate the molecular mechanisms of PTH-stimulated fra-2 induction, transcriptional and translational regulators were used. The protein synthesis inhibitor, cycloheximide (CHX), was administered to osteoblastic cultures, with or without PTHrP stimulation (Fig. 4AGo). CHX alone led to an induction of fra-2 mRNA typical of an immediate early response gene. CHX in combination with PTHrP also resulted in high levels of fra-2 expression, with a trend toward increased expression vs. CHX alone. Actinomycin D pretreatment (1 h) of MC3T3-E1 cells resulted in an abrogation of PTHrP stimulation of fra-2 mRNA after 3 h (Fig. 4Go, B and C), suggesting that the PTHrP effect is dependent on transcription.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 4. Northern blot analysis of steady-state fra-2 mRNA levels from MC3T3-E1 cells treated with CHX (A) or actinomycin D (B and C) and PTHrP. A, Plot of Northern blot analysis of MC3T3-E1 cells treated with CHX (1 µg/ml), PTHrP (0.1 µM), or a combination of CHX and PTHrP. The mean ± SEM of cpm (fra-2, relative to 18S, then expressed as T/C) from three experiments is plotted. At 1 h, PTHrP-treated cells had elevated fra-2 expression vs. control and CHX (P < 0.05); and at 3 h, all treatment groups were significantly elevated vs. control (P < 0.01). B, Representative plot of MC3T3-E1 cells pretreated with actinomycin D (1 µg/ml) then PTHrP (0.1 µM) for 3 h, followed by total RNA isolation and Northern blot analysis for fra-2 gene expression. C, Plot of mean ± SEM of cpm (fra-2, relative to 18S) from two experiments; actinomycin D significantly reduced the PTHrP-stimulated fra-2 mRNA (P < 0.001).

 
PTH-induced fra-2 expression in vivo
A single administration of PTH (20 µg) over the calvaria of mice was effective in inducing an increase of more than 7-fold in steady-state fra-2 mRNA expression in bone vs. vehicle-injected or noninjected controls (Fig. 5Go). The time response for fra-2 induction in vivo is demonstrated in Fig. 6Go. There was maximal expression of steady-state fra-2 mRNA 1 h after injection; and by 8 h, levels returned to baseline values. The expression of c-fos in these calvaria followed a pattern similar to that of fra-2.



View larger version (23K):
[in this window]
[in a new window]
  		Figure 5. Northern blot analysis of PTH regulation of steady-state fra-2 mRNA levels in vivo. PTH (20 µg) or vehicle only was injected sc over the calvaria. After 1 h, calvaria was dissected from PTH-treated, vehicle-treated, or noninjected controls. Total RNA was isolated and Northern blot analysis performed for fra-2. A, Representative blot; B, plot of mean ± SEM of cpm (fra-2 x 100, relative to 18S; n = 3/group).

 


View larger version (22K):
[in this window]
[in a new window]
  		Figure 6. Northern blot analysis of temporal PTH regulation of steady-state fra-2 and c-fos mRNA levels in vivo. PTH (20µg) was injected sc over the calvaria. After 0, 1, 3, 8, and 12 h, mice were killed, calvaria dissected, and total RNA isolated. Northern blot to detect fra-2 and c-fos gene expression was performed. A, Representative blot; B, plot of mean ± SEM of cpm (fra-2 or c-fos relative to 18S; T/C; n = 5/group).

 
PTH induces AP-1 DNA binding activity and Fra-2 protein
To determine whether the PTH-induced fra-2 gene expression resulted in an increase in AP-1 binding activity and specifically an increase in nuclear fra-2 protein, EMSAs were performed. Extracts from PTH- and PTHrP-treated MC3T3-E1 cells were incubated with an oligonucleotide probe containing the consensus AP-1 sequence. Figure 7Go shows that PTH and PTHrP treatment both resulted in a shift in the AP-1 binding that was indicative of an increase in the nuclear accumulation of AP-1 protein. This shift was nearly abolished with the addition of 0.25 µg unlabeled AP-1 oligonucleotide. A strong Fra-2 supershift was present in both PTH- and PTHrP-treated cultures, supporting the finding of Fra-2 protein in the nucleus 3 h after treatment. A detectable, but much lighter, supershift was also present with an antibody to CREB. At 8 h after PTHrP-treatment, AP-1 shift and supershifted nuclear protein levels of Fra-2 were reduced, compared with 3 h, and were similar to control levels (Fig. 7BGo). In comparison with other Fos family members (c-Fos, Fos B, and Fra-1), Fra-2 was the most highly expressed 3 h after PTHrP treatment (Fig. 8Go). Western blot analysis confirmed the specific up-regulation of Fra-2, at the protein level, with PTH and PTHrP treatment (Fig. 9Go).



View larger version (65K):
[in this window]
[in a new window]
  		Figure 7. EMSA. Nuclear extracts from MC3T3-E1 cells (PTH- or PTHrP-treated, 0.1 µM) incubated with radiolabeled AP-1 consensus site, with or without unlabeled competitor (comp; 10x, lane 11, or 25x, lane 12) and with or without Fra-2 or CREB antibodies. A, HeLa extract (lanes 1–3) was run as a positive control for AP-1, and probe without nuclear extracts as a negative control (lane 4). PTH and PTHrP treatment (3 h) resulted in increased AP-1 protein that was supershifted with Fra-2 antibody (lanes 9 and 14). B, MC3T3-E1 cell extract from untreated cells (lanes 1 and 4) or PTHrP treatment 0.1 µM for 3 h (lanes 2 and 5) or 8 h (lanes 3 and 6), with or without Fra-2 antibody supershift (lanes 4–6). Peak nuclear protein binding is detected at 3 h.

 


View larger version (74K):
[in this window]
[in a new window]
  		Figure 8. EMSA. Nuclear extracts from MC3T3-E1 cells (PTH- or PTHrP-treated, 0.1 µM, 3 h) incubated with radiolabeled AP-1 consensus site and with or without Fra-2, Fra-1, Fos B, or c-Fos antibodies. The greatest supershift was found with the Fra-2 antibodies.

 


View larger version (20K):
[in this window]
[in a new window]
  		Figure 9. Western blot analysis of nuclear proteins isolated from MC3T3-E1 cells treated with PTHrP (top) or PTH (bottom) for 3 h. PTH and PTHrP increased Fra-2 proteins in nuclear extracts from osteoblastic cells.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
AP-1 is one of the most widely studied transcription factors. The AP-1 protein components are encoded by immediate-early genes, and AP-1 binding sites are found in numerous genes. Examples of genes containing AP-1 sites that are important in bone are osteocalcin, type I collagen, interleukin-6, M-CSF, and collagenase-3 (12, 13, 14, 25, 26). Findings that PTH modulates members of the AP-1 family is likely to be important for the biologic activities of PTH and PTHrP. It is well known that PTH up-regulates c-fos; but, to our knowledge, effects of PTH or PTHrP to stimulate fra-2 in bone have not been well described.

The sequences of c-fos and fra-2 are very similar, with highly conserved intron-exon structures (27). The similarity of structure suggests that both originated from a single ancestral gene. In concert with this, Fra-2 and Fos proteins are able to form heterodimers with Jun family members (28, 29). Additionally, Fra-2 can support osteoclast differentiation in place of c-Fos; although to a much lower extent than c-Fos or Fra-1 (30). Evaluation of fra-2 during development indicates that expression is high in bone but has a different spatial distribution than c-fos. Specifically, in situ hybridization for fra-2 revealed expression in the bony and cartilaginous side of the growth plate and not in the perichondrium during embryonic development, whereas c-fos is expressed in the perichondrial growth region of the cartilaginous skeleton (31). Functionally, other differences have been noted in keratinocytes, where Fra-2:Jun B heterodimers negatively regulate AP-1-mediated gene expression but c-Fos:Jun B heterodimers activate AP-1 transcriptional activity (32). In contrast, in osteoblasts, overexpression of fra-2 and jun-D activates (while c-fos and c-jun suppress) osteocalcin expression (18, 33). Because many genes expressed during both proliferation and differentiation stages contain AP-1 target sequences, mechanisms for both the induction and suppression of gene expression through AP-1 sites are likely to be operative in bone. This may also explain the diversity of effects PTH has on genes active in the bone microenvironment that contain AP-1 sites.

Interestingly, the studies reported here indicate differences of PTH induction of fra-2, comparing in vitro and in vivo experiments. A higher dose of PTH is required to stimulate gene expression of fra-2 than c-fos in vitro. Detectable and significant levels of c-fos are induced with as little as 1.0 pM PTH (1–34) (4); whereas increases in fra-2 seem to require a higher dose. However, the in vivo studies resulted in similar levels of expression of c-fos and fra-2 with PTH injection. Similarly, the time course of PTH-mediated fra-2 expression in vitro is different from that reported for c-fos or c-jun (3, 4). The increase in fra-2 expression in vitro is maintained over a longer time period than that of c-fos or c-jun. The significance of this duration effect is unclear, but it suggests that AP-1 family members likely have distinct roles in response to extracellular signals in the bone microenvironment. Given the reported negative influence of Fra-2 and Jun D on collagenase expression (34), Fra-2 could be involved in a negative feedback response to PTH effects. Other in vitro studies, comparing c-fos and fra-2 expression in fibroblasts, noted that both were induced by phorbol ester but that fra-2 transcripts were delayed, relative to c-fos (35). The delayed expression of fra-2 may be explained by findings that c-fos is responsible, in part, for the up-regulation of fra-2 because of AP-1 sites in the fra-2 promoter (36). Data are sparse regarding the induction of fra-2 in vivo, especially relative to its induction by PTH in bone.

The translation of PTH-induced fra-2 mRNA into protein was evidenced by Western blot analysis and gel shift analysis, which demonstrated increased AP-1 consensus site binding of nuclear extracts from PTH-treated cells vs. vehicle-treated cells. The Fra-2 protein comprised a large portion of the AP-1 shifted band, as evidenced by the strong supershift with a Fra-2 antibody. This suggests that Fra-2 could play a major role in PTH effects in osteoblasts. Similar to previous reports, a CREB antibody was also capable of supershifting the PTH-induced AP-1 shift (37); although this was minimal, compared with the Fra-2 response. CREB has been reported to interact at AP-1 sites and repress AP-1 transcriptional activity (32, 38).

During osteoblast differentiation, Fra-2 and Jun D are the most abundant AP-1 family members, and inhibition of fra-2 with antisense oligonucleotides results in a suppression of osteoblast differentiation (18). This suggests that PTH may act on osteoblasts to promote differentiation through stimulation of fra-2. However, because we and others have previously reported that PTH inhibits osteoblast differentiation in vitro (39, 40), coinduction of other AP-1 family members such as fra-1 or c-jun, or unrelated transcription factors, may be responsible for counteracting this effect of fra-2. Recent evidence indicates that PTH regulates the collagenase-3 promoter via the interaction of the AP-1 site and the runt binding domain site in UMR 106–01 cells (37). Overexpression of c-fos, c-jun, osteoblast-specific factor-2, and core binding factor-ß increased the response to PTH in UMR 106–01 cells; whereas overexpression of Fra-2 and Jun D decreased basal and PTH-induced collagenase-3 activity in primary osteoblasts (34). Although little information is available regarding the induction of fra-2 by PTH in this model, our data similarly support findings that other AP-1 family members, such as fra-2, may be responsible for PTH effects on downstream target genes.

The identification of fra-2 up-regulation, both in vitro and in vivo, is a valuable addition to the repertoire of transcriptional mediators induced by PTH. Furthermore, these data indicate that complex changes in AP-1 member binding to DNA is likely active in the signaling of PTH to evoke its anabolic and catabolic actions in bone.


   Acknowledgments
 
Diane Robins and Arno Scheller are acknowledged for their assistance in technical aspects of the EMSAs.


   Footnotes
 
1 This work was supported by NIH Grant DK-53904 and the Center for Biorestoration of Oral Health at the University of Michigan. Back

Received August 29, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VLJ, Kronenberg HM, Mulligan RC 1994 Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277–289[Abstract/Free Full Text]
  2. Strewler GJ 2000 Mechanisms of disease: the physiology of parathyroid hormone-related protein. N Engl J Med 342:177–185[Free Full Text]
  3. Clohisy JC, Scott DK, Brakenhoff KD, Quinn CO, Partridge NC 1992 Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol Endocrinol 6:1834–1842[Abstract]
  4. McCauley LK, Koh AJ, Beecher CA, Rosol TJ 1997 The proto-oncogene c-fos is transcriptionally regulated by PTH and PTHrP in a cAMP-dependent manner in osteoblastic cells. Endocrinology 138:5427–5433[Abstract/Free Full Text]
  5. Pearman AT, Chou WY, Bergman KD, Pulumati MR, Partridge NC 1996 Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J Biol Chem 271:25715–25721[Abstract/Free Full Text]
  6. Lee K, Deeds JD, Chiba S, Un-No M, Bond AT, Segre GV 1994 Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: In situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 134:441–450[Abstract]
  7. Liang JD, Hock JM, Sandusky GE, Santerre RF, Onyia JE 1999 Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1–34. Calcif Tissue Int 65:369–373[CrossRef][Medline]
  8. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443–448[Abstract/Free Full Text]
  9. Grigoriadis AE, Wang ZQ, Wagner EF 1995 Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet 11:436–441[CrossRef][Medline]
  10. Herdegen T, Leah JD 1998 Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos, and Krox, and CREB/ATF proteins. Brain Res Rev 28:370–490[CrossRef][Medline]
  11. Curran T, Franza BR 1988 Fos and Jun: the AP-1 connection. Cell 55:395–397[CrossRef][Medline]
  12. Stein GS, Lian JB, Van Wijnen AJ, Montecino M 1996 Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76:593–629[Abstract/Free Full Text]
  13. Keller ET, Chang C, Ershler WB 1996 Inhibition of NFkappaß activity through maintenance of Ikappaß levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271:26267–26275[Abstract/Free Full Text]
  14. Rubin J, Fan D, Wade A, Murphy TC, Gewant H, Nanes MS, Fan X, Moerenhout M, Hofstetter W 2000 Transcriptional regulation of the expression of macrophage colony stimulating factor. Mol Cell Endocrinol 160:193–202[CrossRef][Medline]
  15. McCabe LR, Kockz M, Lian J, Stein J, Stein G 1995 Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. Exp Cell Res 218:255–262[CrossRef][Medline]
  16. Jochum W, David JP, Elliott C, Wutz A, Plenk H, Matsuo K, Wagner EF 2000 Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6:980–984[CrossRef][Medline]
  17. Sabatakos G, Sims NA, Chen K, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R 2000 Overexpression of {Delta}FosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985–990[CrossRef][Medline]
  18. McCabe LR, Banerjee C, Kundu R, Harrison RJ, Dobner PR, Stein JL, Lian JB, Stein GS 1996 Developmental expression and activities of specific Fos and Jun proteins are functionally related to osteoblast maturation: Role of fra-2 and jun D. Endocrinology 137:4398–4408[Abstract]
  19. Koe RC, Clohisy JC, Tyson DR, Pulumati MR, Cook TF, Partridge NC 1997 Parathyroid hormone versus phorbol ester stimulation of activator protein-1 gene family members in rat osteosarcoma cells. Calcif Tissue Int 61:52–58[CrossRef][Medline]
  20. McCauley LK, Koh AJ, Beecher CA, Cui Y, Decker JD, Francheschi RT 1995 Effects of differentiation and transforming growth factor beta on PTH/PTHrP receptor mRNA levels in MC3T3–E1 cells. J Bone Miner Res 10:1243–1255[Medline]
  21. McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT 1996 PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem 61:638–647[CrossRef][Medline]
  22. McCauley LK, Beecher CA, Melton ME, Werkmeister JR, Jüppner H, Abou-Samra AB, Segre GV, Rosol TJ 1994 Transforming growth factor ß regulates steady state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells. Mol Cell Endocrinol 101:331–336[CrossRef][Medline]
  23. Grone A, McCauley LK, Capen CC, Rosol TJ 1997 PTH/PTHrP receptor expression in humoral hypercalcemia of malignancy in nude mice with the canine apocrine adenocarcinoma (CAC-8). J Endocrinol 153:123–129[Abstract/Free Full Text]
  24. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499–2501[Free Full Text]
  25. Partridge NC, Bloch SR, Pearman AT 1994 Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression. J Cell Biochem 55:321–327[CrossRef][Medline]
  26. Chung KY, Agarwal A, Uitto J, Mauviel A 1996 An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 271:3272–3278[Abstract/Free Full Text]
  27. Foletta VC 1996 Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol 74:121–133[Medline]
  28. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P 1988 c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55:917–924[CrossRef][Medline]
  29. Nishina H, Sato H, Suzuki T, Sato M, Iba H 1990 Isolation and characterization of fra-2, an additional member of the fos gene family. Proc Natl Acad Sci USA 87:3619–3623[Abstract/Free Full Text]
  30. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF 2000 Fos/1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184–187[CrossRef][Medline]
  31. Carrasco D, Bravo R 1995 Tissue-specific expression of the fos-related transcription factor fra-2 during mouse development. Oncogene 10:1069–1079[Medline]
  32. Rutberg SE, Adams TL, Olive M, Alexander N, Vinson C, Yuspa SH 1999 CRE DNA binding proteins bind to the AP-1 target sequence and suppress AP-1 transcriptional activity in mouse keratinocytes. Oncogene 18:1569–1579[CrossRef][Medline]
  33. Schule R, Umesono K, Mangelsdorf DJ, Bolada J, Pike JW, Evans RM 1990 Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell 61:497–504[CrossRef][Medline]
  34. Winchester SK, Selvamurugan N, D’Alonzo RC, Partridge NC 2000 Developmental regulation of collagenase-3 mRNA in normal differentiating osteoblasts through the activator protein-1 and the runt domain binding sites. J Biol Chem 275:23310–23318[Abstract/Free Full Text]
  35. Yoshida T, Suzuki T, Sato H, Nishina H, Iba H 1993 Analysis of fra-2 gene expression. Nucleic Acids Res 21:2715–2721[Abstract/Free Full Text]
  36. Sonobe MH, Yoshida T, Murakami M, Kameda T, Iba H 1995 The fra-2 promoter can respond to serum-stimulation through AP-1 complexes. Oncogene 10:689–696[Medline]
  37. Selvamurugan N, Chou W, Pearman AT, Pulumati MR, Partridge NC 1998 Parathyroid hormone regulates the rat collagenase-3 promoter in osteoblastic cells through the cooperative interaction of the activator protein-1 site and the runt domain binding sequence. J Biol Chem 273:10647–10657[Abstract/Free Full Text]
  38. Hai T, Curran T 1991 Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Science USA 88:3720–3724[Abstract/Free Full Text]
  39. Koh AJ, Beecher CA, Rosol TJ, McCauley LK 1999 3',5'-Cyclic adenosine monophosphate activation in osteoblastic cells: effects of parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140:3154–3162[Abstract/Free Full Text]
  40. Bellows CG, Ishida H, Aubin JE, Heersche JNM 1990 Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinology 127:3111–3116[Abstract]



This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. Yu, R. T. Franceschi, M. Luo, X. Zhang, D. Jiang, Y. Lai, Y. Jiang, J. Zhang, and G. Xiao
Parathyroid Hormone Increases Activating Transcription Factor 4 Expression and Activity in Osteoblasts: Requirement for Osteocalcin Gene Expression
Endocrinology, April 1, 2008; 149(4): 1960 - 1968.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Q. Pirih, A. Tang, I. C. Ozkurt, J. M. Nervina, and S. Tetradis
Nuclear Orphan Receptor Nurr1 Directly Transactivates the Osteocalcin Gene in Osteoblasts
J. Biol. Chem., December 17, 2004; 279(51): 53167 - 53174.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Chang, A. Rewari, M. Centrella, and T. L. McCarthy
Fos-related Antigen 2 Controls Protein Kinase A-induced CCAAT/Enhancer-binding Protein {beta} Expression in Osteoblasts
J. Biol. Chem., October 8, 2004; 279(41): 42438 - 42444.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
I. C. Ozkurt, F. Q. Pirih, and S. Tetradis
Parathyroid Hormone Induces E4bp4 Messenger Ribonucleic Acid Expression Primarily through Cyclic Adenosine 3',5'-Monophosphate Signaling in Osteoblasts
Endocrinology, August 1, 2004; 145(8): 3696 - 3703.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Chen, A. J. Koh, N. S. Datta, J. Zhang, E. T. Keller, G. Xiao, R. T. Franceschi, N. J. D'Silva, and L. K. McCauley
Impact of the Mitogen-activated Protein Kinase Pathway on Parathyroid Hormone-related Protein Actions in Osteoblasts
J. Biol. Chem., July 9, 2004; 279(28): 29121 - 29129.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. Demiralp, H.-L. Chen, A. J. Koh, E. T. Keller, and L. K. McCauley
Anabolic Actions of Parathyroid Hormone during Bone Growth Are Dependent on c-fos
Endocrinology, October 1, 2002; 143(10): 4038 - 4047.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Zayzafoon, S. Botolin, and L. R. McCabe
p38 and Activating Transcription Factor-2 Involvement in Osteoblast Osmotic Response to Elevated Extracellular Glucose
J. Biol. Chem., September 27, 2002; 277(40): 37212 - 37218.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-L. Chen, B. Demiralp, A. Schneider, A. J. Koh, C. Silve, C.-Y. Wang, and L. K. McCauley
Parathyroid Hormone and Parathyroid Hormone-related Protein Exert Both Pro- and Anti-apoptotic Effects in Mesenchymal Cells
J. Biol. Chem., May 24, 2002; 277(22): 19374 - 19381.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gopalakrishnan, H. Ouyang, M. J. Somerman, L. K. McCauley, and R. T. Franceschi
Matrix {gamma}-Carboxyglutamic Acid Protein Is a Key Regulator of PTH-Mediated Inhibition of Mineralization in MC3T3-E1 Osteoblast-Like Cells
Endocrinology, October 1, 2001; 142(10): 4379 - 4388.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mccauley, L. K.
Right arrow Articles by McCabe, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mccauley, L. K.
Right arrow Articles by McCabe, L. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOHEXIMIDE
*PARATHYROID HORMONE

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals